The Combination of Enoxaparin, Glycoprotein IIb/IIIa Inhibitors and an Early Invasive Approach among Acute Coronary Syndrome Patients

Journal of Invasive Cardiology

Volumn 16, Issue 2, 2004, Pages 46-51

  Lee, David S ^a   Bhatt, Deepak L ^a   Moliterno, David J ^a   Peacock, William F ^a   Ellis, Stephen G ^a   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Acute coronary syndromes; Angioplasty; Anticoagulation; Antiplatelet drugs

Indexed keywords

ABCIXIMAB; BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN;

ADULT; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; MALE; PERCUTANEOUS CORONARY INTERVENTION; SIDE EFFECT;

ACUTE DISEASE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CORONARY DISEASE; DRUG THERAPY, COMBINATION; ENOXAPARIN; FACTOR XA; FEMALE; HUMANS; MALE; MIDDLE AGED; OHIO; PILOT PROJECTS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES; SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 1142310649     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events Study Group. N Engl J Med 1997;337:447-452.
2. Antman EM. Enoxaparin versus unfractionated heparin for unstable angina or non-Q wave myocardial infarction: A double-blind, placebo-controlled parallel-group, multi-center trial. Rationale, study design and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators. Am Heart J 1998;135:S353-S360.
3. The Thrombolysis in Myocardial Infarction (TIMI) 11A Investigators. Dose-ranging trial of enoxaparin for unstable angina: Results of TIMI 11A. J Am Coll Cardiol 1997;29:1474-1482.
4. Weitz JI. Low molecular weight heparins. N Engl J Med 1997;337:688-698.
5. Futterman LG, Lemberg L. Low molecular weight heparin: An antithrombotic agent whose time has come. Am J Crit Care 1999;8:520-523.
6. Purcell H, Fox KM. Current roles and future possibilities for low molecular weight heparins in unstable angina. Eur Heart J 1998;19(Suppl K):K18-K23.
7. Huang JN, Shimamura A. Low molecular weight heparins. Hematol Oncol Clin North Am 1998;12:1251-1281, vi-vii.
8. Antman Em, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation 1999;100:1593-1601.
9. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602-1608.
10. Knight CJ, Panesar M, Wilson DJ, et al. Increased platelet responsiveness following coronary stenting. Heparin as a possible aetiological factor in stent thrombosis. Eur Heart 1998;19:1239-1248.
11. Montalescot G, Philippe F, Ankri A, et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: Beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation 1998;98:294-299.
12. Montalescot G, Collet JP, Lison L, et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000;36:110-114.
13. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low molecular weight heparin and with a direct thrombin inhibitor. Circulation 1998;97:251-256.
14. Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of low molecular weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: Results from the ESSENCE randomized trial. Efficacy and safety of subcutaneous enoxaparin in non-Q wave coronary events (unstable angina or non-Q wave myocardial infarction). Circulation 1998;97:1702-1707.
15. Kereiakes DJ, Fry E, Matthai W, et al. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE" guys finish first. J Invas Cardiol 2000;12(Suppl A):1A-5A.
16. Bhatt D, Lee B, Casterella P, et al. Safety of comcomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: Results of the CRUISE Study. J Am Coll Cardiol 2003 (in press).
17. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. J Engl J Med 1994;330:956-961.
18. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study. Lancet 1997;349:1429-1435.
19. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor or blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336:1689-1696.
20. The PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Platelet IIb/IIIa Antagonism for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network. Circulation 1998;97:2386-2395.
21. The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Qwave myocardial infarction. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study. N Engl J Med 1998;338:1488-1497.
22. The PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study. N Engl J Med 1998;338:1498-1505.
23. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Study. N Engl J Med 1998;339:436-443.
24. The EPISTENT Investigators. Randomised, placebo-controlled and balloon angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352:87-92.
25. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at 6 months. The EPIC Investigators. Lancet 1994;343:881-886.
26. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta-3 blockade with percutaneous coronary intervention. The EPIC Investigators. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complications. JAMA 1997;278:479-484.
27. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-663.
28. Goodman S. The INTERACT Trial. Scientific Sessions of the American College of Cardiology. Atlanta, GA, 2002.
29. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial. Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.
30. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST segment elevation myocardial infarction - Summary article: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2002;40:1366-1374.
31. Ferguson JJ, Antman EM, Bates E, et al. The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI: The NICE 3 Study (Abstr). J Am Coll Cardiol 2001;37:365A.
32. Cohen M, Theroux P, Borzak S, et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II Study. The Antithrombotic Combination Using Tirofiban and Enoxaparin. Am Heart J 2002;144:470-477.
33. Martin JL, Fry ETA, Sanderink GJ, et al. Pharmacokinetic study of enoxaparin in patients undergoing coronary intervention after treatment with subcutaneous enoxaparin in acute coronary syndromes. The PEPCI Study. Eur Heart J 2001;22:14.
34. Moliterno DJ, Hermiller JB, Kereiakes DJ, et al. A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study. J Am Coll Cardiol 2003;42:1132-1139.